Haura E - Search Results

1

Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.

Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Bepler G, et al. Among authors: haura e. J Thorac Oncol. 2011 Mar;6(3):553-8. doi: 10.1097/JTO.0b013e31820b8d88. J Thorac Oncol. 2011. PMID: 21289520 Free PMC article. Clinical Trial.

2

Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.

Haura EB. Haura EB. Cancer Control. 2001 Jul-Aug;8(4):326-36. doi: 10.1177/107327480100800404. Cancer Control. 2001. PMID: 11483886 Free article. Review.

3

Management of advanced non-small cell lung cancer: current trends.

Haura EB. Haura EB. Curr Opin Pulm Med. 2002 Jul;8(4):251-6. doi: 10.1097/00063198-200207000-00002. Curr Opin Pulm Med. 2002. PMID: 12055385 Review.

4

Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.

Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Simon GR, et al. Among authors: haura e. Cancer Control. 2003 Sep-Oct;10(5):388-95. doi: 10.1177/107327480301000506. Cancer Control. 2003. PMID: 14581894 Free article. Clinical Trial.

5

Neutropenic enterocolitis (typhilitis) associated with docetaxel therapy in a patient with non-small-cell lung cancer: case report and review of literature.

D'Amato G, Rocha Lima C, Mahany JJ, Muro-Cacho C, Haura EB. D'Amato G, et al. Lung Cancer. 2004 Jun;44(3):381-90. doi: 10.1016/j.lungcan.2003.11.018. Lung Cancer. 2004. PMID: 15140552 Review.

6

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer.

Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. Bepler G, et al. Among authors: haura e. J Clin Oncol. 2004 May 15;22(10):1878-85. doi: 10.1200/JCO.2004.12.002. J Clin Oncol. 2004. PMID: 15143080

7

Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies.

Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G. Haura EB, et al. Clin Lung Cancer. 2004 Sep;6(2):113-22. doi: 10.3816/CLC.2004.n.025. Clin Lung Cancer. 2004. PMID: 15476597 Review.

8

Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.

Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald MC, Bepler G, Patz EF Jr. Howard BA, et al. Among authors: haura e. Lung Cancer. 2004 Dec;46(3):313-23. doi: 10.1016/j.lungcan.2004.05.013. Lung Cancer. 2004. PMID: 15541816

9

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance.

Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Bepler G, et al. Among authors: haura e. Lung Cancer. 2005 Feb;47(2):183-92. doi: 10.1016/j.lungcan.2004.07.043. Lung Cancer. 2005. PMID: 15639717

10

EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer.

Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB. Ferraro B, et al. J Clin Oncol. 2005 Mar 20;23(9):1921-6. doi: 10.1200/JCO.2005.08.127. J Clin Oncol. 2005. PMID: 15774784

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

246 results

Search Page

Filters